New test identifies high-risk childhood brain tumors, improving treatment decisions
Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common ...
pharmaphorum1d
Roche taps Oxford BioTherapeutics for cancer drug discovery
Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...
News-Medical.Net on MSN7d
New technique effectively identifies aggressive medulloblastoma
Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma-the most common type of malignant brain tumour in children-and potentially sparing young ...
Pharmabiz4h
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Agilent’s PD-L1 IHC 28-8 pharmDx gets added indications under EU IVDR1 for NSLC
Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...
EurekAlert!8d
New test identifies high-risk childhood brain tumours, improving treatment decisions
Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common type of malignant brain tumour in children—and potentially sparing young ...
Morningstar10d
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...
Business Wire10d
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide ...